DW-4301 is under clinical development by Daewon Pharmaceutical and currently in Phase II for Dyslipidemia. According to GlobalData, Phase II drugs for Dyslipidemia have a 52% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how DW-4301’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

DW-4301 overview

DW-4301 is under development for the treatment of hyperlipidemia, primary hypercholesterolemia and complex dyslipidemia. The therapeutic candidate is administered through oral route. The therapeutic candidate is a new chemical entity.

Daewon Pharmaceutical overview

Daewon Pharm Co Ltd (Daewon) is a pharmaceutical company. It manufactures and supplies pharmaceutical and medicinal products. The company offers antipyretics, analgesics and anti-inflammatory drugs, antimicrobial drugs, respiratory drugs, cardiovascular drugs, gastrointestinal drugs, and antidiabetic drugs. It also offers products in form of tablets, solutions, film coated tablets, hard capsules, vial and ampoule, soft capsules, and sugar-coated tablets. Daewon conducts research in areas of drug efficacy evaluation, synthesis molecules, botanical drug research and biologics research. The company markets its products in China, Vietnam, Taiwan, Singapore, Hong Kong, Japan, Mongolia, Malaysia, Cambodia, Myanmar, South Korea, the Philippines, and Indonesia. Daewon is headquartered in Seoul, South Korea.

For a complete picture of DW-4301’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.